{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:41:51Z","timestamp":1792572111350,"version":"4.5.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2026NSFSC1599"],"award-info":[{"award-number":["2026NSFSC1599"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"DOI":"10.1007\/s00281-026-01090-z","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:28:38Z","timestamp":1792510118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lineage plasticity\u2013driven immunometabolic state transitions in advanced prostate cancer: biomarkers and therapeutic stratification"],"prefix":"10.1007","volume":"48","author":[{"given":"Haowen","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"1090_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60654-z","volume":"16","author":"K Mizuno","year":"2025","unstructured":"Mizuno K, Ku SY, Venkadakrishnan VB et al (2025) Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer. Nat Commun 16:5543. https:\/\/doi.org\/10.1038\/s41467-025-60654-z","journal-title":"Nat Commun"},{"key":"1090_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.21147\/j.issn.1000-9604.2025.01.07","volume":"37","author":"T Ding","year":"2025","unstructured":"Ding T, He L, Lin G et al (2025) Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancer. Chin J Cancer Res 37:90\u2013114. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2025.01.07","journal-title":"Chin J Cancer Res"},{"key":"1090_CR3","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/jco.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Huang J, Alumkal JJ et al (2018) Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol 36:2492\u20132503. https:\/\/doi.org\/10.1200\/jco.2017.77.6880","journal-title":"J Clin Oncol"},{"key":"1090_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/jco.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M et al (2020) Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 38:395\u2013405. https:\/\/doi.org\/10.1200\/jco.19.01638","journal-title":"J Clin Oncol"},{"key":"1090_CR5","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","volume":"39","author":"Y Kfoury","year":"2021","unstructured":"Kfoury Y, Baryawno N, Severe N et al (2021) Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell 39:1464-1478.e8. https:\/\/doi.org\/10.1016\/j.ccell.2021.09.005","journal-title":"Cancer Cell"},{"key":"1090_CR6","doi-asserted-by":"publisher","first-page":"9949","DOI":"10.1038\/s41467-024-54364-1","volume":"15","author":"A Kiviaho","year":"2024","unstructured":"Kiviaho A, Eerola SK, Kallio HML et al (2024) Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. Nat Commun 15:9949. https:\/\/doi.org\/10.1038\/s41467-024-54364-1","journal-title":"Nat Commun"},{"key":"1090_CR7","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.ccr-24-0060","volume":"30","author":"MC Dallos","year":"2024","unstructured":"Dallos MC, Obradovic AZ, McCann P et al (2024) Androgen deprivation therapy drives a distinct immune phenotype in localized prostate cancer. Clin Cancer Res 30:5218\u20135230. https:\/\/doi.org\/10.1158\/1078-0432.ccr-24-0060","journal-title":"Clin Cancer Res"},{"key":"1090_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/2159-8290.cd-24-0559","volume":"15","author":"LN Chesner","year":"2025","unstructured":"Chesner LN, Polesso F, Graff JN et al (2025) Androgen receptor inhibition increases MHC class I expression and improves immune response in prostate cancer. Cancer Discov 15:481\u2013494. https:\/\/doi.org\/10.1158\/2159-8290.cd-24-0559","journal-title":"Cancer Discov"},{"key":"1090_CR9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","volume":"637","author":"A Lyu","year":"2025","unstructured":"Lyu A, Fan Z, Clark M et al (2025) Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature 637:1207\u20131217. https:\/\/doi.org\/10.1038\/s41586-024-08290-3","journal-title":"Nature"},{"key":"1090_CR10","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41416-024-02762-z","volume":"131","author":"M Pujana-Vaquerizo","year":"2024","unstructured":"Pujana-Vaquerizo M, Bozal-Basterra L, Carracedo A (2024) Metabolic adaptations in prostate cancer. Br J Cancer 131:1250\u20131262. https:\/\/doi.org\/10.1038\/s41416-024-02762-z","journal-title":"Br J Cancer"},{"key":"1090_CR11","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1038\/emboj.2011.158","volume":"30","author":"CE Massie","year":"2011","unstructured":"Massie CE, Lynch A, Ramos-Montoya A et al (2011) The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 30:2719\u20132733. https:\/\/doi.org\/10.1038\/emboj.2011.158","journal-title":"EMBO J"},{"key":"1090_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver BS, Chapinski C, Wongvipat J et al (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575\u2013586. https:\/\/doi.org\/10.1016\/j.ccr.2011.04.008","journal-title":"Cancer Cell"},{"key":"1090_CR13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","volume":"32","author":"EG Bluemn","year":"2017","unstructured":"Bluemn EG, Coleman IM, Lucas JM et al (2017) Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 32:474-489.e6. https:\/\/doi.org\/10.1016\/j.ccell.2017.09.003","journal-title":"Cancer Cell"},{"key":"1090_CR14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM et al (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22:298\u2013305. https:\/\/doi.org\/10.1038\/nm.4045","journal-title":"Nat Med"},{"key":"1090_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku SY, Rosario S, Wang Y et al (2017) Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355:78\u201383. https:\/\/doi.org\/10.1126\/science.aah4199","journal-title":"Science"},{"key":"1090_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu P, Zhang Z, Benelli M et al (2017) SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355:84\u201388. https:\/\/doi.org\/10.1126\/science.aah4307","journal-title":"Science"},{"key":"1090_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran H, Rickman DS, Park K et al (2011) Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 1:487\u2013495. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0130","journal-title":"Cancer Discov"},{"key":"1090_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","volume":"30","author":"E Dardenne","year":"2016","unstructured":"Dardenne E, Beltran H, Benelli M et al (2016) N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30:563\u2013577. https:\/\/doi.org\/10.1016\/j.ccell.2016.09.005","journal-title":"Cancer Cell"},{"key":"1090_CR19","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1172\/JCI127961","volume":"129","author":"A Berger","year":"2019","unstructured":"Berger A, Brady NJ, Bareja R et al (2019) N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. J Clin Invest 129:3924\u20133940. https:\/\/doi.org\/10.1172\/JCI127961","journal-title":"J Clin Invest"},{"key":"1090_CR20","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1038\/s41467-021-26042-z","volume":"12","author":"P Cejas","year":"2021","unstructured":"Cejas P, Xie Y, Font-Tello A et al (2021) Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun 12:5775. https:\/\/doi.org\/10.1038\/s41467-021-26042-z","journal-title":"Nat Commun"},{"key":"1090_CR21","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/s43018-024-00838-6","volume":"5","author":"R Romero","year":"2024","unstructured":"Romero R, Chu T, Gonz\u00e1lez-Robles TJ et al (2024) The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1. Nat Cancer 5:1641\u20131659. https:\/\/doi.org\/10.1038\/s43018-024-00838-6","journal-title":"Nat Cancer"},{"key":"1090_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08133-6","volume":"10","author":"H Guo","year":"2019","unstructured":"Guo H, Ci X, Ahmed M et al (2019) ONECUT2 is a driver of neuroendocrine prostate cancer. Nat Commun 10:278. https:\/\/doi.org\/10.1038\/s41467-018-08133-6","journal-title":"Nat Commun"},{"key":"1090_CR23","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1126\/science.abn0478","volume":"377","author":"JM Chan","year":"2022","unstructured":"Chan JM, Zaidi S, Love JR et al (2022) Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling. Science 377:1180\u20131191. https:\/\/doi.org\/10.1126\/science.abn0478","journal-title":"Science"},{"key":"1090_CR24","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.14336\/AD.2024.0421","volume":"16","author":"M Tufail","year":"2025","unstructured":"Tufail M, Huang Y-Q, Hu J-J et al (2025) Cellular aging and senescence in cancer: a holistic review of cellular fate determinants. Aging Dis 16:1483\u20131512. https:\/\/doi.org\/10.14336\/AD.2024.0421","journal-title":"Aging Dis"},{"key":"1090_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1646","volume":"16","author":"BN Rodriguez","year":"2024","unstructured":"Rodriguez BN, Huang H, Chia JJ, Hoffmann A (2024) The noncanonical NF\u03baB pathway: regulatory mechanisms in health and disease. WIREs Mech Dis 16:e1646. https:\/\/doi.org\/10.1002\/wsbm.1646","journal-title":"WIREs Mech Dis"},{"key":"1090_CR26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","volume":"606","author":"X Guan","year":"2022","unstructured":"Guan X, Polesso F, Wang C et al (2022) Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature 606:791\u2013796. https:\/\/doi.org\/10.1038\/s41586-022-04522-6","journal-title":"Nature"},{"key":"1090_CR27","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.ccell.2023.10.006","volume":"41","author":"JE Hawley","year":"2023","unstructured":"Hawley JE, Obradovic A, Dallos MC et al (2023) Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. Cancer Cell 41:1972-1988.e5. https:\/\/doi.org\/10.1016\/j.ccell.2023.10.006","journal-title":"Cancer Cell"},{"key":"1090_CR28","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.annonc.2025.05.008","volume":"36","author":"C Gratzke","year":"2025","unstructured":"Gratzke C, \u00d6zg\u00fcro\u011flu M, Peer A et al (2025) Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study. Ann Oncol 36:964\u2013975. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.008","journal-title":"Ann Oncol"},{"key":"1090_CR29","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.annonc.2025.05.007","volume":"36","author":"JN Graff","year":"2025","unstructured":"Graff JN, Burotto M, Fong PC et al (2025) Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study. Ann Oncol 36:976\u2013987. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.007","journal-title":"Ann Oncol"},{"key":"1090_CR30","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1158\/1078-0432.ccr-22-3743","volume":"29","author":"B Bhinder","year":"2023","unstructured":"Bhinder B, Ferguson A, Sigouros M et al (2023) Immunogenomic landscape of neuroendocrine prostate cancer. Clin Cancer Res 29:2933\u20132943. https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-3743","journal-title":"Clin Cancer Res"},{"key":"1090_CR31","doi-asserted-by":"publisher","DOI":"10.1172\/jci175217","volume":"134","author":"SY Ku","year":"2024","unstructured":"Ku SY, Wang Y, Garcia MM et al (2024) Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer. J Clin Invest 134:e175217. https:\/\/doi.org\/10.1172\/jci175217","journal-title":"J Clin Invest"},{"key":"1090_CR32","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1038\/s41467-026-71121-8","volume":"17","author":"L Brea","year":"2026","unstructured":"Brea L, Shi H, Keo V et al (2026) FOXA1 loss drives basal\/squamous de-differentiation of prostate cancer and induces an immunosuppressive tumor microenvironment. Nat Commun 17:4572. https:\/\/doi.org\/10.1038\/s41467-026-71121-8","journal-title":"Nat Commun"},{"key":"1090_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/s0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney C, Bracarda S, Sternberg CN et al (2021) Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer: the phase III IPATential150 trial. Lancet 398:131\u2013142. https:\/\/doi.org\/10.1016\/s0140-6736(21)00580-8","journal-title":"Lancet"},{"key":"1090_CR34","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.eururo.2024.12.015","volume":"87","author":"JS de Bono","year":"2025","unstructured":"de Bono JS, He M, Shi Z et al (2025) Final overall survival and molecular data associated with clinical outcomes in patients receiving ipatasertib and abiraterone in the phase III IPATential150 trial. Eur Urol 87:672\u2013682. https:\/\/doi.org\/10.1016\/j.eururo.2024.12.015","journal-title":"Eur Urol"},{"key":"1090_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","volume":"37","author":"K Fizazi","year":"2026","unstructured":"Fizazi K, Clarke NW, De Santis M et al (2026) Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol 37:53\u201368. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.004","journal-title":"Ann Oncol"},{"key":"1090_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.ccr-18-1912","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran H, Oromendia C, Danila DC et al (2019) A phase II trial of the Aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Clin Cancer Res 25:43\u201351. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-1912","journal-title":"Clin Cancer Res"},{"key":"1090_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21615-4","volume":"12","author":"L Brady","year":"2021","unstructured":"Brady L, Kriner M, Coleman I et al (2021) Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat Commun 12:1426. https:\/\/doi.org\/10.1038\/s41467-021-21615-4","journal-title":"Nat Commun"},{"key":"1090_CR38","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/pros.24497","volume":"83","author":"LS Graham","year":"2023","unstructured":"Graham LS, Haffner MC, Sayar E et al (2023) Clinical, pathologic, and molecular features of amphicrine prostate cancer. Prostate 83:641\u2013648. https:\/\/doi.org\/10.1002\/pros.24497","journal-title":"Prostate"},{"key":"1090_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.70094","volume":"77","author":"X Yi","year":"2025","unstructured":"Yi X, Han Z, Tang Y et al (2025) Liquid-liquid phase separation of AR orchestrated by melatonin sensitizes prostate cancer to ferroptosis via MCM5\/NRF2 axis collapse. J Pineal Res 77:e70094. https:\/\/doi.org\/10.1111\/jpi.70094","journal-title":"J Pineal Res"},{"key":"1090_CR40","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","volume":"559","author":"A Calcinotto","year":"2018","unstructured":"Calcinotto A, Spataro C, Zagato E et al (2018) IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature 559:363\u2013369. https:\/\/doi.org\/10.1038\/s41586-018-0266-0","journal-title":"Nature"},{"key":"1090_CR41","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","volume":"4","author":"MK Bakht","year":"2023","unstructured":"Bakht MK, Yamada Y, Ku SY et al (2023) Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer Inst 4:699\u2013715. https:\/\/doi.org\/10.1038\/s43018-023-00539-6","journal-title":"Nat Cancer Inst"},{"key":"1090_CR42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/pros.24630","volume":"84","author":"MP Labrecque","year":"2024","unstructured":"Labrecque MP, Brown LG, Coleman IM et al (2024) Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer. Prostate 84:100\u2013110. https:\/\/doi.org\/10.1002\/pros.24630","journal-title":"Prostate"},{"key":"1090_CR43","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/pros.24146","volume":"81","author":"HS Basu","year":"2021","unstructured":"Basu HS, Wilganowski N, Robertson S et al (2021) Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities. Prostate 81:799\u2013811. https:\/\/doi.org\/10.1002\/pros.24146","journal-title":"Prostate"},{"key":"1090_CR44","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.01.018","volume":"35","author":"M Reina-Campos","year":"2019","unstructured":"Reina-Campos M, Linares JF, Duran A et al (2019) Increased serine and one-carbon pathway metabolism by PKC\u03bb\/\u03b9 deficiency promotes neuroendocrine prostate cancer. Cancer Cell 35:385-400.e9. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.018","journal-title":"Cancer Cell"},{"key":"1090_CR45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2416882121","volume":"121","author":"G Varuzhanyan","year":"2024","unstructured":"Varuzhanyan G, Chen CC, Freeland J et al (2024) PGC-1\u03b1 drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity. Proc Natl Acad Sci U S A 121:e2416882121. https:\/\/doi.org\/10.1073\/pnas.2416882121","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1090_CR46","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1016\/j.ccell.2023.10.009","volume":"41","author":"CC Chen","year":"2023","unstructured":"Chen CC, Tran W, Song K et al (2023) Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation. Cancer Cell 41:2066-2082.e9. https:\/\/doi.org\/10.1016\/j.ccell.2023.10.009","journal-title":"Cancer Cell"},{"key":"1090_CR47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2322203121","volume":"121","author":"S Zaidi","year":"2024","unstructured":"Zaidi S, Park J, Chan JM et al (2024) Single-cell analysis of treatment-resistant prostate cancer: implications of cell state changes for cell surface antigen-targeted therapies. Proc Natl Acad Sci U S A 121:e2322203121. https:\/\/doi.org\/10.1073\/pnas.2322203121","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1090_CR48","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D et al (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162:1229\u20131241. https:\/\/doi.org\/10.1016\/j.cell.2015.08.016","journal-title":"Cell"},{"key":"1090_CR49","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3390\/cancers12030537","volume":"12","author":"R Sriram","year":"2020","unstructured":"Sriram R, Van Criekinge M, DeLos SJ et al (2020) Elevated tumor lactate and efflux in high-grade prostate cancer demonstrated by hyperpolarized 13C magnetic resonance spectroscopy of prostate tissue slice cultures. Cancers 12:537. https:\/\/doi.org\/10.3390\/cancers12030537","journal-title":"Cancers"},{"key":"1090_CR50","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/0008-5472.CAN-12-1949","volume":"72","author":"T Fiaschi","year":"2012","unstructured":"Fiaschi T, Marini A, Giannoni E et al (2012) Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor\u2013stroma interplay. Cancer Res 72:5130\u20135140. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1949","journal-title":"Cancer Res"},{"key":"1090_CR51","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1038\/s41388-019-0688-7","volume":"38","author":"G Comito","year":"2019","unstructured":"Comito G, Iscaro A, Bacci M et al (2019) Lactate modulates CD4\u207a T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via the TLR8\/miR21 axis. Oncogene 38:3681\u20133695. https:\/\/doi.org\/10.1038\/s41388-019-0688-7","journal-title":"Oncogene"},{"key":"1090_CR52","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, Singer K, Koehl GE et al (2016) LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab 24:657\u2013671. https:\/\/doi.org\/10.1016\/j.cmet.2016.08.011","journal-title":"Cell Metab"},{"key":"1090_CR53","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio OR, Chu NQ, Szabo AL et al (2014) Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513:559\u2013563. https:\/\/doi.org\/10.1038\/nature13490","journal-title":"Nature"},{"key":"1090_CR54","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","volume":"591","author":"MJ Watson","year":"2021","unstructured":"Watson MJ, Vignali PDA, Mullett SJ et al (2021) Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature 591:645\u2013651. https:\/\/doi.org\/10.1038\/s41586-020-03045-2","journal-title":"Nature"},{"key":"1090_CR55","doi-asserted-by":"publisher","first-page":"432","DOI":"10.21147\/j.issn.1000-9604.2025.03.11","volume":"37","author":"L Sun","year":"2025","unstructured":"Sun L, Zhao G, Wang S, Li N (2025) Immune cell metabolism in cancer drug resistance: advances in target discovery and clinical translation. Chin J Cancer Res 37:432\u2013445. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2025.03.11","journal-title":"Chin J Cancer Res"},{"key":"1090_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5758","volume":"11","author":"MJ Watt","year":"2019","unstructured":"Watt MJ, Clark AK, Selth LA et al (2019) Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med 11:eaau5758. https:\/\/doi.org\/10.1126\/scitranslmed.aau5758","journal-title":"Sci Transl Med"},{"key":"1090_CR57","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1073\/pnas.1808834116","volume":"116","author":"G Zadra","year":"2019","unstructured":"Zadra G, Ribeiro CF, Chetta P et al (2019) Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci U S A 116:631\u2013640. https:\/\/doi.org\/10.1073\/pnas.1808834116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1090_CR58","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.cmet.2014.01.019","volume":"19","author":"S Yue","year":"2014","unstructured":"Yue S, Li J, Lee SY et al (2014) Cholesteryl ester accumulation induced by PTEN loss and PI3K\/AKT activation underlies human prostate cancer aggressiveness. Cell Metab 19:393\u2013406. https:\/\/doi.org\/10.1016\/j.cmet.2014.01.019","journal-title":"Cell Metab"},{"key":"1090_CR59","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","volume":"569","author":"F Veglia","year":"2019","unstructured":"Veglia F, Tyurin VA, Blasi M et al (2019) Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature 569:73\u201378. https:\/\/doi.org\/10.1038\/s41586-019-1118-2","journal-title":"Nature"},{"key":"1090_CR60","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","volume":"54","author":"S Xu","year":"2021","unstructured":"Xu S, Chaudhary O, Rodr\u00edguez-Morales P et al (2021) Uptake of oxidized lipids by CD36 promotes lipid peroxidation and dysfunction in CD8\u207a T cells in tumors. Immunity 54:1561-1577.e7. https:\/\/doi.org\/10.1016\/j.immuni.2021.05.003","journal-title":"Immunity"},{"key":"1090_CR61","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","volume":"21","author":"H Wang","year":"2020","unstructured":"Wang H, Franco F, Tsui YC et al (2020) CD36-mediated metabolic adaptation supports regulatory T-cell survival and function in tumors. Nat Immunol 21:298\u2013308. https:\/\/doi.org\/10.1038\/s41590-019-0589-5","journal-title":"Nat Immunol"},{"key":"1090_CR62","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nm.2172","volume":"16","author":"DL Herber","year":"2010","unstructured":"Herber DL, Cao W, Nefedova Y et al (2010) Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med 16:880\u2013886. https:\/\/doi.org\/10.1038\/nm.2172","journal-title":"Nat Med"},{"key":"1090_CR63","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1172\/JCI99397","volume":"128","author":"R Mishra","year":"2018","unstructured":"Mishra R, Haldar S, Suchanti S et al (2018) Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. J Clin Invest 128:4472\u20134484. https:\/\/doi.org\/10.1172\/JCI99397","journal-title":"J Clin Invest"},{"key":"1090_CR64","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1158\/2326-6066.cir-23-1105","volume":"12","author":"M Praharaj","year":"2024","unstructured":"Praharaj M, Shen F, Lee AJ et al (2024) Metabolic reprogramming of tumor-associated macrophages using glutamine antagonist JHU083 drives tumor immunity in myeloid-rich prostate and bladder cancers. Cancer Immunol Res 12:854\u2013875. https:\/\/doi.org\/10.1158\/2326-6066.cir-23-1105","journal-title":"Cancer Immunol Res"},{"key":"1090_CR65","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1158\/0008-5472.CAN-04-0465","volume":"64","author":"PC Rodriguez","year":"2004","unstructured":"Rodriguez PC, Quiceno DG, Zabaleta J et al (2004) Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64:5839\u20135849. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0465","journal-title":"Cancer Res"},{"key":"1090_CR66","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1158\/0008-5472.CAN-17-3752","volume":"78","author":"K Kolijn","year":"2018","unstructured":"Kolijn K, Verhoef EI, Smid M et al (2018) Epithelial-mesenchymal transition in human prostate cancer demonstrates enhanced immune evasion marked by IDO1 expression. Cancer Res 78:4671\u20134679. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-3752","journal-title":"Cancer Res"},{"key":"1090_CR67","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s00262-019-02394-w","volume":"68","author":"CD Zahm","year":"2019","unstructured":"Zahm CD, Johnson LE, McNeel DG (2019) Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy. Cancer Immunol Immunother 68:1661\u20131669. https:\/\/doi.org\/10.1007\/s00262-019-02394-w","journal-title":"Cancer Immunol Immunother"},{"key":"1090_CR68","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/s1470-2045(19)30274-8","volume":"20","author":"GV Long","year":"2019","unstructured":"Long GV, Dummer R, Hamid O et al (2019) Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma: ECHO-301\/KEYNOTE-252. Lancet Oncol 20:1083\u20131097. https:\/\/doi.org\/10.1016\/s1470-2045(19)30274-8","journal-title":"Lancet Oncol"},{"key":"1090_CR69","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1172\/JCI96268","volume":"128","author":"P Jayaprakash","year":"2018","unstructured":"Jayaprakash P, Ai M, Liu A et al (2018) Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J Clin Invest 128:5137\u20135149. https:\/\/doi.org\/10.1172\/JCI96268","journal-title":"J Clin Invest"},{"key":"1090_CR70","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1158\/1078-0432.CCR-15-1181","volume":"22","author":"BG Leclerc","year":"2016","unstructured":"Leclerc BG, Charlebois R, Chouinard G et al (2016) CD73 expression is an independent prognostic factor in prostate cancer. Clin Cancer Res 22:158\u2013166. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1181","journal-title":"Clin Cancer Res"},{"key":"1090_CR71","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1158\/1078-0432.CCR-22-0612","volume":"28","author":"EA Lim","year":"2022","unstructured":"Lim EA, Bendell JC, Falchook GS et al (2022) Phase Ia\/b study of AZD4635 as monotherapy or combined with durvalumab in patients with solid tumours. Clin Cancer Res 28:4871\u20134884. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0612","journal-title":"Clin Cancer Res"},{"key":"1090_CR72","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","volume":"22","author":"NE Scharping","year":"2021","unstructured":"Scharping NE, Rivadeneira DB, Menk AV et al (2021) Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol 22:205\u2013215. https:\/\/doi.org\/10.1038\/s41590-020-00834-9","journal-title":"Nat Immunol"},{"key":"1090_CR73","doi-asserted-by":"publisher","first-page":"138","DOI":"10.21147\/j.issn.1000-9604.2024.02.04","volume":"36","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Guo F, Wang Y (2024) Hypoxic tumor microenvironment: destroyer of natural killer cell function. Chin J Cancer Res 36:138\u2013150. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2024.02.04","journal-title":"Chin J Cancer Res"},{"key":"1090_CR74","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1126\/science.1164097","volume":"324","author":"KE Wellen","year":"2009","unstructured":"Wellen KE, Hatzivassiliou G, Sachdeva UM et al (2009) ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324:1076\u20131080. https:\/\/doi.org\/10.1126\/science.1164097","journal-title":"Science"},{"key":"1090_CR75","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmet.2014.06.004","volume":"20","author":"JV Lee","year":"2014","unstructured":"Lee JV, Carrer A, Shah S et al (2014) Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab 20:306\u2013319. https:\/\/doi.org\/10.1016\/j.cmet.2014.06.004","journal-title":"Cell Metab"},{"key":"1090_CR76","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/0008-5472.CAN-21-0914","volume":"82","author":"L Ippolito","year":"2022","unstructured":"Ippolito L, Comito G, Parri M et al (2022) Lactate rewires lipid metabolism and sustains a metabolic-epigenetic axis in prostate cancer. Cancer Res 82:1267\u20131282. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-0914","journal-title":"Cancer Res"},{"key":"1090_CR77","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","volume":"574","author":"D Zhang","year":"2019","unstructured":"Zhang D, Tang Z, Huang H et al (2019) Metabolic regulation of gene expression by histone lactylation. Nature 574:575\u2013580. https:\/\/doi.org\/10.1038\/s41586-019-1678-1","journal-title":"Nature"},{"key":"1090_CR78","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/ni.3796","volume":"18","author":"PS Liu","year":"2017","unstructured":"Liu PS, Wang H, Li X et al (2017) \u03b1-Ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol 18:985\u2013994. https:\/\/doi.org\/10.1038\/ni.3796","journal-title":"Nat Immunol"},{"key":"1090_CR79","doi-asserted-by":"publisher","unstructured":"Qin L, Liang T, Zhu X et al (2025) Senescent macrophages and the lung cancer microenvironment: a new perspective on tumor immune evasion. Aging Dis 16:3453\u20133465. https:\/\/doi.org\/10.14336\/AD.2024.1404","DOI":"10.14336\/AD.2024.1404"},{"key":"1090_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.70000","volume":"17","author":"F Moradi Kashkooli","year":"2025","unstructured":"Moradi Kashkooli F, Mirala F, Tehrani MHH (2025) Mechanical forces in tumor growth and treatment: perspectives from biology, physics, engineering, and mathematical modeling. WIREs Mech Dis 17:e70000. https:\/\/doi.org\/10.1002\/wsbm.70000","journal-title":"WIREs Mech Dis"},{"key":"1090_CR81","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.18632\/oncotarget.1482","volume":"4","author":"MK Herroon","year":"2013","unstructured":"Herroon MK, Rajagurubandara E, Hardaway AL et al (2013) Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms. Oncotarget 4:2108\u20132123. https:\/\/doi.org\/10.18632\/oncotarget.1482","journal-title":"Oncotarget"},{"key":"1090_CR82","doi-asserted-by":"publisher","first-page":"64854","DOI":"10.18632\/oncotarget.11712","volume":"7","author":"JD Diedrich","year":"2016","unstructured":"Diedrich JD, Rajagurubandara E, Herroon MK, Mahapatra G, H\u00fcttemann M, Podgorski I (2016) Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1\u03b1 activation. Oncotarget 7:64854\u201364877. https:\/\/doi.org\/10.18632\/oncotarget.11712","journal-title":"Oncotarget"},{"key":"1090_CR83","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221007","volume":"220","author":"XF Li","year":"2023","unstructured":"Li XF, Selli C, Zhou HL et al (2023) Macrophages promote anti-androgen resistance in prostate cancer bone disease. J Exp Med 220:e20221007. https:\/\/doi.org\/10.1084\/jem.20221007","journal-title":"J Exp Med"},{"key":"1090_CR84","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41413-021-00178-6","volume":"10","author":"JA Siddiqui","year":"2022","unstructured":"Siddiqui JA, Seshacharyulu P, Muniyan S et al (2022) GDF15 promotes prostate cancer bone metastasis and colonization through osteoblastic CCL2 and RANKL activation. Bone Res 10:6. https:\/\/doi.org\/10.1038\/s41413-021-00178-6","journal-title":"Bone Res"},{"key":"1090_CR85","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.70000","volume":"76","author":"LW Lin","year":"2024","unstructured":"Lin LW, Lin TH, Swain S et al (2024) Melatonin inhibits ET-1 production to break crosstalk between prostate cancer and bone cells: implication for osteoblastic bone metastasis treatment. J Pineal Res 76:e70000. https:\/\/doi.org\/10.1111\/jpi.70000","journal-title":"J Pineal Res"},{"key":"1090_CR86","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/s0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u2013822. https:\/\/doi.org\/10.1016\/s0140-6736(10)62344-6","journal-title":"Lancet"},{"key":"1090_CR87","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/nejmoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213\u2013223. https:\/\/doi.org\/10.1056\/nejmoa1213755","journal-title":"N Engl J Med"},{"key":"1090_CR88","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/nejmoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN et al (2021) Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091\u20131103. https:\/\/doi.org\/10.1056\/nejmoa2107322","journal-title":"N Engl J Med"},{"key":"1090_CR89","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41391-021-00486-2","volume":"25","author":"M Alshalalfa","year":"2022","unstructured":"Alshalalfa M, Seldon C, Franco I et al (2022) Clinicogenomic characterization of prostate cancer liver metastases. Prostate Cancer Prostatic Dis 25:366\u2013369. https:\/\/doi.org\/10.1038\/s41391-021-00486-2","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1090_CR90","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu J, Green MD, Li S et al (2021) Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T-cell elimination. Nat Med 27:152\u2013164. https:\/\/doi.org\/10.1038\/s41591-020-1131-x","journal-title":"Nat Med"},{"key":"1090_CR91","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13056","volume":"54","author":"K Liu","year":"2021","unstructured":"Liu K, Jing N, Wang D et al (2021) A novel mouse model for liver metastasis of prostate cancer reveals dynamic tumour\u2013immune cell communication. Cell Prolif 54:e13056. https:\/\/doi.org\/10.1111\/cpr.13056","journal-title":"Cell Prolif"},{"key":"1090_CR92","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature14347","volume":"520","author":"G Gundem","year":"2015","unstructured":"Gundem G, Van Loo P, Kremeyer B et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520:353\u2013357. https:\/\/doi.org\/10.1038\/nature14347","journal-title":"Nature"},{"key":"1090_CR93","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43018-023-00692-y","volume":"5","author":"EW Warner","year":"2024","unstructured":"Warner EW, Van der Eecken K, Murtha AJ et al (2024) Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping. Nat Cancer 5:114\u2013130. https:\/\/doi.org\/10.1038\/s43018-023-00692-y","journal-title":"Nat Cancer"},{"key":"1090_CR94","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006070","volume":"5","author":"SJ Nelson","year":"2013","unstructured":"Nelson SJ, Kurhanewicz J, Vigneron DB et al (2013) Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C]pyruvate. Sci Transl Med 5:198ra108. https:\/\/doi.org\/10.1126\/scitranslmed.3006070","journal-title":"Sci Transl Med"},{"key":"1090_CR95","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41391-019-0180-z","volume":"23","author":"HY Chen","year":"2020","unstructured":"Chen HY, Aggarwal R, Bok RA et al (2020) Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. Prostate Cancer Prostatic Dis 23:269\u2013276. https:\/\/doi.org\/10.1038\/s41391-019-0180-z","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1090_CR96","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S et al (2021) [1\u2077\u2077Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer: a randomised, open-label, phase 2 trial. Lancet 397:797\u2013804. https:\/\/doi.org\/10.1016\/s0140-6736(21)00237-3","journal-title":"Lancet"},{"key":"1090_CR97","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/s1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L et al (2022) PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [1\u2077\u2077Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer: a biomarker analysis from the TheraP trial. Lancet Oncol 23:1389\u20131397. https:\/\/doi.org\/10.1016\/s1470-2045(22)00605-2","journal-title":"Lancet Oncol"},{"key":"1090_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233260","volume":"15","author":"LS Graham","year":"2020","unstructured":"Graham LS, Montgomery B, Cheng HH et al (2020) Mismatch repair deficiency in metastatic prostate cancer: response to PD-1 blockade and standard therapies. PLoS ONE 15:e0233260. https:\/\/doi.org\/10.1371\/journal.pone.0233260","journal-title":"PLoS ONE"},{"key":"1090_CR99","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1200\/jco-24-02637","volume":"43","author":"G Leone","year":"2025","unstructured":"Leone G, Wong YNS, Jones RJ et al (2025) Nivolumab and ipilimumab for metastatic castration-resistant prostate cancer with an immunogenic signature: the multicenter, two-cohort, phase II NEPTUNES study. J Clin Oncol 43:3070\u20133080. https:\/\/doi.org\/10.1200\/jco-24-02637","journal-title":"J Clin Oncol"},{"key":"1090_CR100","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/nejmoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382:2091\u20132102. https:\/\/doi.org\/10.1056\/nejmoa1911440","journal-title":"N Engl J Med"},{"key":"1090_CR101","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1200\/jco.18.01731","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Halabi S, Luo J et al (2019) Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J Clin Oncol 37:1120\u20131129. https:\/\/doi.org\/10.1200\/jco.18.01731","journal-title":"J Clin Oncol"},{"key":"1090_CR102","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1172\/jci131041","volume":"130","author":"H Beltran","year":"2020","unstructured":"Beltran H, Romanel A, Conteduca V et al (2020) Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J Clin Invest 130:1653\u20131668. https:\/\/doi.org\/10.1172\/jci131041","journal-title":"J Clin Invest"},{"key":"1090_CR103","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/2159-8290.cd-23-0754","volume":"14","author":"GM Franceschini","year":"2024","unstructured":"Franceschini GM, Quaini O, Mizuno K et al (2024) Noninvasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation. Cancer Discov 14:424\u2013445. https:\/\/doi.org\/10.1158\/2159-8290.cd-23-0754","journal-title":"Cancer Discov"},{"key":"1090_CR104","unstructured":"U.S. Food and Drug Administration (2026) FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-na\u00efve or -sensitive prostate cancer. 12 June 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-capivasertib-abiraterone-and-prednisone-pten-deficient-androgen-pathway-modulation"},{"key":"1090_CR105","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1158\/0008-5472.can-14-0992","volume":"75","author":"J Escamilla","year":"2015","unstructured":"Escamilla J, Schokrpur S, Liu C et al (2015) CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Res 75:950\u2013962. https:\/\/doi.org\/10.1158\/0008-5472.can-14-0992","journal-title":"Cancer Res"},{"key":"1090_CR106","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1200\/jco.23.00233","volume":"41","author":"ES Antonarakis","year":"2023","unstructured":"Antonarakis ES, Park SH, Goh JC et al (2023) Pembrolizumab plus olaparib for previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: KEYLYNK-010. J Clin Oncol 41:3839\u20133850. https:\/\/doi.org\/10.1200\/jco.23.00233","journal-title":"J Clin Oncol"},{"key":"1090_CR107","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/s1470-2045(23)00451-5","volume":"24","author":"R Aggarwal","year":"2023","unstructured":"Aggarwal R, Starzinski S, de Kouchkovsky I et al (2023) Single-dose 1\u2077\u2077Lu-PSMA-617 followed by maintenance pembrolizumab in metastatic castration-resistant prostate cancer. Lancet Oncol 24:1266\u20131276. https:\/\/doi.org\/10.1016\/s1470-2045(23)00451-5","journal-title":"Lancet Oncol"},{"key":"1090_CR108","unstructured":"U.S. Food and Drug Administration (2025) FDA expands Pluvicto\u2019s metastatic castration-resistant prostate cancer indication. 28 March 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication"},{"key":"1090_CR109","doi-asserted-by":"publisher","first-page":"645","DOI":"10.14336\/AD.2024.0327","volume":"16","author":"D Li","year":"2025","unstructured":"Li D, Yu Q, Wu R et al (2025) Chronobiology of the tumor microenvironment: implications for therapeutic strategies and circadian-based interventions. Aging Dis 16:645\u2013657. https:\/\/doi.org\/10.14336\/AD.2024.0327","journal-title":"Aging Dis"},{"key":"1090_CR110","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.70001","volume":"17","author":"N Rajinikanth","year":"2025","unstructured":"Rajinikanth N, Chauhan R, Prabakaran S (2025) Harnessing noncanonical proteins for next-generation drug discovery and diagnosis. WIREs Mech Dis 17:e70001. https:\/\/doi.org\/10.1002\/wsbm.70001","journal-title":"WIREs Mech Dis"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-026-01090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00281-026-01090-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-026-01090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:03:37Z","timestamp":1792569817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00281-026-01090-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1090"],"URL":"https:\/\/doi.org\/10.1007\/s00281-026-01090-z","relation":{},"ISSN":["1863-2300"],"issn-type":[{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"11 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Throughout this Review, treatment-emergent neuroendocrine prostate cancer (t-NEPC) is used specifically to denote neuroendocrine carcinoma arising after therapy for conventional prostate adenocarcinoma. The term neuroendocrine-like is used to describe partial or molecular neuroendocrine programmes that do not necessarily represent established t-NEPC. When original studies use the broader term NEPC as a study-defined category, that terminology is retained to accurately reflect the reported evidence.\u00a0","order":2,"name":"Ethics","label":"Terminology clarification for neuroendocrine states","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23"}}